Molecules 2013, 18(1), 204-224; doi:10.3390/molecules18010204
Review

Anti-Infectious Agents against MRSA

email, email and * email
Received: 16 October 2012; in revised form: 3 December 2012 / Accepted: 14 December 2012 / Published: 24 December 2012
(This article belongs to the collection Bioactive Compounds)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Clinically useful antibiotics, β-lactams and vancomycin, are known to inhibit bacterial cell wall peptidoglycan synthesis. Methicillin-resistant Staphylococcus aureus (MRSA) has a unique cell wall structure consisting of peptidoglycan and wall teichoic acid. In recent years, new anti-infectious agents (spirohexaline, tripropeptin C, DMPI, CDFI, cyslabdan, 1835F03, and BPH-652) targeting MRSA cell wall biosynthesis have been discovered using unique screening methods. These agents were found to inhibit important enzymes involved in cell wall biosynthesis such as undecaprenyl pyrophosphate (UPP) synthase, FemA, flippase, or UPP phosphatase. In this review, the discovery, the mechanism of action, and the future of these anti-infectious agents are described.
Keywords: MRSA; anti-infectious agents; peptidoglycan; teichoic acid; virulence factors
PDF Full-text Download PDF Full-Text [770 KB, uploaded 18 June 2014 20:00 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Koyama, N.; Inokoshi, J.; Tomoda, H. Anti-Infectious Agents against MRSA. Molecules 2013, 18, 204-224.

AMA Style

Koyama N, Inokoshi J, Tomoda H. Anti-Infectious Agents against MRSA. Molecules. 2013; 18(1):204-224.

Chicago/Turabian Style

Koyama, Nobuhiro; Inokoshi, Junji; Tomoda, Hiroshi. 2013. "Anti-Infectious Agents against MRSA." Molecules 18, no. 1: 204-224.

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert